Skip to main content
Clinical Trials/NCT03602209
NCT03602209
Completed
Not Applicable

Short vs. Long Antibiotic Treatment of Implant-free Osteoarticular Infections

University Hospital, Geneva1 site in 1 country120 target enrollmentMarch 1, 2015

Overview

Phase
Not Applicable
Intervention
Removal of infected implant
Conditions
Implant Infection
Sponsor
University Hospital, Geneva
Enrollment
120
Locations
1
Primary Endpoint
Remission of infection
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The investigators tested the working hypothesis if 4 weeks of systemic antibiotic treatment in implant-related orthopaedic infections is non-inferior to 6 weeks after complete removal of the infected implant. Randomization 1:1.

The study is completed. It halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

Detailed Description

Former description of the study (now completed) Osteoarticular infections related to orthopaedic implants are associated with substantial morbidity, prolongation of hospital stay, and additional costs. Due to the increasing number of patients with orthopaedic implants in Switzerland, similar to the rest of Europe and elsewhere, the number of infections is expected to increase. While the surgical treatment of these infections has been well studied, the ideal duration of antibiotic therapy after removal (explantation) of the infected implant remains unknown. For almost 40 years, the recommended total duration of post-explantation antibiotic therapy has been 6 weeks. This recommendation is based on expert's personal experience rather than on prospective randomized studies. Shorter treatment would decrease antibiotic-related adverse events and costs hospital stay for patients awaiting an eventual reinsertion of a new implant. If physicians and surgeon prescribe antibiotics for 6 weeks, this duration should be at least supported by evidence.

Registry
clinicaltrials.gov
Start Date
March 1, 2015
End Date
May 18, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ilker Uckay

Attending, Docent Dr. med. Ilker Uçkay

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Adult patients (≥17 years old)
  • Total removal of the implant

Exclusion Criteria

  • Primary native joint septic arthritis;
  • Co-trimoxazole prophylaxis because of immunosuppression;
  • Left-side endocarditis;
  • Persistent implant material in the infected area.
  • Infections with tuberculosis; mycobacteria; fungi; brucellosis; borreliosis; nocardiosis; and mycoplasmal osteosynthesis infections

Arms & Interventions

4 weeks of treatment

Intervention: Removal of infected implant

4 weeks of treatment

Intervention: Antibiotic durations

6 weeks of treatment

Intervention: Removal of infected implant

6 weeks of treatment

Intervention: Antibiotic durations

Outcomes

Primary Outcomes

Remission of infection

Time Frame: 12 months

Clinical evaluation

Adverse events

Time Frame: 12 months

Clinical adverse events

Study Sites (1)

Loading locations...

Similar Trials